# TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer

> **NCT03720431** · PHASE1 · UNKNOWN · sponsor: **PharmAbcine** · enrollment: 11 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** TTAC-0001 and pembrolizumab combination

## Key facts

- **NCT ID:** NCT03720431
- **Lead sponsor:** PharmAbcine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-03
- **Primary completion:** 2020-03-18
- **Final completion:** 2022-10-26
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2022-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03720431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03720431, "TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03720431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*